Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?

<b/> PI3K pathway alterations are frequently recurrent in metastatic prostate cancer and are associated with the development of currently incurable castration-resistant disease. Candidate inhibitors that target single PI3K pathway members lack efficacy as demonstrated in multiple clinical trials. In this issue, Pearson and colleagues examine the functional importance of co-occurring PIK3CA and PTEN aberrations using a novel mouse model and demonstrate a synergistic acceleration of tumorigenesis that may be responsible for de novo metastatic prostate cancer. Cancer Discov; 8(6); 682-5. ©2018 AACRSee related article by Pearson et al., p. 764. ©2018 American Association for Cancer Research.